Kodama I, Kamiya K, Toyama J
Department of Circulation, Research Institute of Environmental Medicine, Nagoya University, Japan.
Am J Cardiol. 1999 Nov 4;84(9A):20R-28R. doi: 10.1016/s0002-9149(99)00698-0.
Amiodarone is the most promising drug in the treatment of life-threatening ventricular tachyarrhythmias in patients with significant structural heart disease. The pharmacologic profile of amiodarone is complex and much remains to be clarified about its short- and long-term actions on multiple molecular targets. This article reviews electrophysiologic effects of amiodarone based on previous reports and our own experiments in single cells and multicellular tissue preparations of mammalian hearts. As acute effects, amiodarone inhibits both inward and outward currents. The inhibition of inward sodium and calcium currents (I(Na), I(Ca)) is enhanced in a use- and voltage-dependent manner, resulting in suppression of excitability and conductivity of cardiac tissues especially when stimulated at higher frequencies and in those with less-negative membrane potential. Both voltage- and ligand-gated potassium channel currents (I(K), I(K,Na), I(K,ACh)) are also inhibited at therapeutic levels of drug concentrations. Acutely-administered amiodarone has no consistent effect on the action potential duration (APD). The major and consistent long-term effect of the drug is a moderate APD prolongation with minimal frequency dependence. This prolongation is most likely due to a decrease in the current density of I(K) and I(to). Chronic amiodarone was shown to cause a down-regulation of Kv1.5 messenger ribonucleic acid (mRNA) in rat hearts, suggesting a drug-induced modulation of potassium-channel gene expression. Tissue accumulation of amiodarone and its active metabolite (desethylamiodarone) may modulate the chronic effects, causing variable suppression of excitability and conductivity of the heart through the direct effects of the compounds retained at the sites of action. Amiodarone and desethylamiodarone could antagonize triiodothyronine (T3) action on the heart at cellular or subcellular levels, leading to phenotypic resemblance of long-term amiodarone treatment and hypothyroidism.
胺碘酮是治疗患有严重结构性心脏病且危及生命的室性快速性心律失常患者最有前景的药物。胺碘酮的药理学特性复杂,关于其对多个分子靶点的短期和长期作用仍有许多有待阐明之处。本文基于以往报道以及我们在哺乳动物心脏单细胞和多细胞组织制剂中的实验,综述了胺碘酮的电生理效应。作为急性效应,胺碘酮抑制内向和外向电流。对内向钠电流和钙电流(I(Na)、I(Ca))的抑制以使用和电压依赖性方式增强,导致心脏组织的兴奋性和传导性受到抑制,尤其是在较高频率刺激时以及膜电位较不负极化的组织中。在治疗药物浓度水平时,电压门控和配体门控钾通道电流(I(K)、I(K,Na)、I(K,ACh))也受到抑制。急性给予胺碘酮对动作电位时程(APD)没有一致的影响。该药物主要且一致的长期效应是APD适度延长且频率依赖性最小。这种延长很可能是由于I(K)和I(to)的电流密度降低所致。慢性给予胺碘酮可导致大鼠心脏中Kv1.5信使核糖核酸(mRNA)下调,提示药物诱导的钾通道基因表达调节。胺碘酮及其活性代谢物(去乙基胺碘酮)在组织中的蓄积可能调节慢性效应,通过作用部位留存化合物的直接效应导致心脏兴奋性和传导性受到不同程度的抑制。胺碘酮和去乙基胺碘酮可在细胞或亚细胞水平拮抗三碘甲状腺原氨酸(T3)对心脏的作用,导致长期胺碘酮治疗与甲状腺功能减退的表型相似。